Serum and follicular fluid levels of soluble receptor for advanced glycation end-products in women with and without polycystic ovary syndrome.
Extracellular Fluid
IVF
Polycystic Ovary Syndrome
Receptor for Advanced Glycation End Product
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
13
01
2023
accepted:
21
06
2023
medline:
3
7
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Advanced glycation end products (AGEs) are known to associate with the pathogenesis of several chronic diseases via interaction with their corresponding receptor (RAGE). The soluble forms of RAGE (sRAGE) are considered as anti-inflammatory agents by inhibiting the consequent adverse effects of AGE. We aimed at comparing sRAGE levels in the follicular fluid (FF) and serum of women with or without Polycystic Ovary Syndrome (PCOS) who underwent controlled ovarian stimulation for in vitro fertilisation (IVF). A total of forty-five eligible women (26 non-PCOS (control) and 19 patients with PCOS (case)) were included the study. sRAGEs in FF and blood serum were measured using ELISA kit. No statistically significant differences were found in FF and serum sRAGE between case and control groups. Correlation analysis showed a significant and positive relationship between serum levels of sRAGE and FF sRAGE in PCOS (r = 0.639; p = 0.004), in control participants (r = 0.481; p = 0.017), and in total participants (r = 0.552; p = 0.000). Data revealed a statistically significant difference in FF sRAGE concentration among all participants by body mass index (BMI) categories (p = 0.01) and in controls (p = 0.022). Significant differences were found for all the nutrients and AGEs consumption according to Food Frequency Questionnaire in both groups (p = 0.0001). A significant reverse relationship was found between FF levels of sRAGE and AGE in PCOS (r = -0.513; p = 0.025). The concentration of sRAGE in serum and FF is the same in PCOS and control. The present study revealed for the first time that there are no statistically significant differences between the concentration of serum sRAGE and FF sRAGE among Iranian women with and without PCOS. However, BMI and dietary intake of AGEs have more significant effects on sRAGE concentration in Iranian women. Future studies in developed and developing countries with larger sample sizes are required to determine the long-term consequences of chronic AGE over consumption and the optimal strategies for minimizing AGE-related pathology, specifically in low income and developing countries.
Sections du résumé
BACKGROUND
BACKGROUND
Advanced glycation end products (AGEs) are known to associate with the pathogenesis of several chronic diseases via interaction with their corresponding receptor (RAGE). The soluble forms of RAGE (sRAGE) are considered as anti-inflammatory agents by inhibiting the consequent adverse effects of AGE. We aimed at comparing sRAGE levels in the follicular fluid (FF) and serum of women with or without Polycystic Ovary Syndrome (PCOS) who underwent controlled ovarian stimulation for in vitro fertilisation (IVF).
METHODS
METHODS
A total of forty-five eligible women (26 non-PCOS (control) and 19 patients with PCOS (case)) were included the study. sRAGEs in FF and blood serum were measured using ELISA kit.
RESULTS
RESULTS
No statistically significant differences were found in FF and serum sRAGE between case and control groups. Correlation analysis showed a significant and positive relationship between serum levels of sRAGE and FF sRAGE in PCOS (r = 0.639; p = 0.004), in control participants (r = 0.481; p = 0.017), and in total participants (r = 0.552; p = 0.000). Data revealed a statistically significant difference in FF sRAGE concentration among all participants by body mass index (BMI) categories (p = 0.01) and in controls (p = 0.022). Significant differences were found for all the nutrients and AGEs consumption according to Food Frequency Questionnaire in both groups (p = 0.0001). A significant reverse relationship was found between FF levels of sRAGE and AGE in PCOS (r = -0.513; p = 0.025). The concentration of sRAGE in serum and FF is the same in PCOS and control.
CONCLUSION
CONCLUSIONS
The present study revealed for the first time that there are no statistically significant differences between the concentration of serum sRAGE and FF sRAGE among Iranian women with and without PCOS. However, BMI and dietary intake of AGEs have more significant effects on sRAGE concentration in Iranian women. Future studies in developed and developing countries with larger sample sizes are required to determine the long-term consequences of chronic AGE over consumption and the optimal strategies for minimizing AGE-related pathology, specifically in low income and developing countries.
Identifiants
pubmed: 37391740
doi: 10.1186/s13048-023-01224-z
pii: 10.1186/s13048-023-01224-z
pmc: PMC10311803
doi:
Substances chimiques
Receptor for Advanced Glycation End Products
0
Glycation End Products, Advanced
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127Informations de copyright
© 2023. The Author(s).
Références
J Endocrinol. 2013 Aug 29;218(3):331-7
pubmed: 23823020
Int J Reprod Biomed. 2017 Sep;15(9):575-582
pubmed: 29662966
Diabetes. 2011 Sep;60(9):2379-85
pubmed: 21771973
Nutrients. 2015 Dec 04;7(12):10129-44
pubmed: 26690206
Public Health Nutr. 2010 May;13(5):654-62
pubmed: 19807937
Hormones (Athens). 2014 Jan-Mar;13(1):65-73
pubmed: 24722128
Redox Biol. 2014 Jan 09;2:411-29
pubmed: 24624331
Cytokine. 2015 Jun;73(2):265-9
pubmed: 25802195
J Assist Reprod Genet. 2017 Nov;34(11):1507-1513
pubmed: 28825156
Nutrients. 2022 Feb 24;14(5):
pubmed: 35267940
Fertil Steril. 2009 Feb;91(2):456-88
pubmed: 18950759
Hum Reprod. 2011 Mar;26(3):604-10
pubmed: 21233108
Mol Nutr Food Res. 2021 Jan;65(1):e1900934
pubmed: 32246887
Hum Reprod. 2003 Nov;18(11):2289-93
pubmed: 14585875
Curr Pharm Des. 2012;18(3):270-82
pubmed: 22229564
Mech Ageing Dev. 2015 Jan;145:18-25
pubmed: 25681682
J Clin Endocrinol Metab. 2009 Dec;94(12):5174-80
pubmed: 19890027
Int J Endocrinol. 2014;2014:657607
pubmed: 24575131
Fertil Steril. 2006 Aug;86(2):411-7
pubmed: 16762348
Diabetes Obes Metab. 2005 Jul;7(4):448-54
pubmed: 15955132
Redox Biol. 2021 Jun;42:101958
pubmed: 33839083
Mol Cell Endocrinol. 2013 Jul 5;373(1-2):91-7
pubmed: 23261983
Diabetes Metab Res Rev. 2011 Jul;27(5):488-92
pubmed: 21337488
Ann Clin Biochem. 2014 Mar;51(Pt 2):248-57
pubmed: 23982266
Obes Rev. 2020 Jun;21(6):e13000
pubmed: 31950676
Surg Obes Relat Dis. 2016 Aug;12(7):1337-1341
pubmed: 27134202
J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92
pubmed: 24151290
Reproduction. 2017 Mar;153(3):285-292
pubmed: 27965400
Minerva Ginecol. 2019 Jun;71(3):211-223
pubmed: 31089072
J Am Diet Assoc. 2010 Jun;110(6):911-16.e12
pubmed: 20497781
Clin Endocrinol (Oxf). 2007 Jan;66(1):103-9
pubmed: 17201808
Int J Obes (Lond). 2012 Nov;36(11):1412-7
pubmed: 22828946
Recent Prog Horm Res. 2001;56:1-21
pubmed: 11237208
Fertil Steril. 2014 Aug;102(2):460-468.e3
pubmed: 24933120
J Clin Endocrinol Metab. 2012 Jul;97(7):2231-42
pubmed: 22508704
J Clin Endocrinol Metab. 2006 Nov;91(11):4628-34
pubmed: 16926247
J Assist Reprod Genet. 2016 Jul;33(7):959-65
pubmed: 27011370
J Clin Endocrinol Metab. 2014 Jun;99(6):E1137-45
pubmed: 24628555
Ann Surg. 2014 Oct;260(4):617-22; discussion 622-4
pubmed: 25203878